ArielF.Grajales-CruzMD

PubMed

• Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
  Othman S Akhtar, Karnav Modi, Jongphil Kim, Lawrence Skelson, Eric Smith, Mohammed A Al-Jumayli, Martine Extermann, Gabriel De Avila, Nathan Parker, Omar Castaneda Pug...> ;Transplantation and Cellular Therapy. 2024 Mar 1
• B-cell maturation antigen expression and clinical features of plasmablastic lymphoma.
  Mammadova, J., Pinilla, J., Dong, N., Zhang, H., Song, J., Shah, B., Saeed, H., Gaballa, S., Grajales-Cruz, A., Isenalumhe, L., Bello, C., Sokol, L., Chavez, J.> ;Ejhaem. 2024 Feb 1
• 2 citations
  Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
  Laura B Oswald, Lisa M Gudenkauf, Xiaoyin Li, Gabriel De Avila, Lauren C Peres, Kedar Kirtane, Brian D Gonzalez, Aasha I Hoogland, Oanh Nguyen, Yvelise Rodriguez, Rach...> ;Cancers. 2023 Sep 25
• 2 citations
  Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
  Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, Lauren C Peres, Melissa Alsina, Christina Bachmeier, Brandon J Blue, Jason Brayer, Sanjay Chandrasekhar, Ariel Grajales C...> ;Blood Advances. 2023 Aug 22
• 22 citations
  Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
  Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury, Hitomi Hosoya, Rebecca M Gonzalez, Christina Copponex, Krista H...> ;Blood Advances. 2022 Dec 27
• 10 citations
  Primary Adrenal Angiosarcoma: A Rare and Potentially Misdiagnosed Tumor.
  Ariel Grajales-Cruz, Francis Baco-Viera, Ernesto Rivé-Mora, Carlos Ramírez-Tanchez, David Tasso, Norma Arroyo-Portela, Elizabeth Calderón, Ilean Joan Padua-Octaviani, ...> ;Cancer Control. 2017 Apr 1
• 3 citations
  Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
  Ashley Rose, Ariel F Grajales-Cruz, Alex Lim, Amber Todd, Celeste M. Bello, Bijal D. Shah, Julio C. Chavez, Javier Pinilla-Ibartz, Hayder Saeed, Jose Sandoval-Sus, Lei...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Feb 1
• 73 citations
  Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
  Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Maryam Sarraf Yazdy, Guilherme ...> ;Clinical Cancer Research. 2020 Jul 15
• Join now to see all

Abstracts/Posters

• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Ariel F Grajales-Cruz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019